Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.35 -0.15 (-0.86%)

Delayed Quote Updated: 10:31 AM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

36 37 Next >

Nvidia, Sarepta, HPE, Citi, EQT: What Sparked Heavy After-Hours Trading In These 5 Stocks? ↗

July 28, 2025

Sarepta stock’s after-hours jump came as the FDA notified the company that it could lift the voluntary pause on the shipments.

Via Stocktwits

Topics Artificial Intelligence Credit Cards

BitMine Immersion, Sarepta Therapeutics, CEA Industries, Super Micro Computer And AMD: Why These 5 Stocks Are On Investors' Radars Today ↗

July 28, 2025

U.S. markets closed mixed on Monday, with the Dow Jones Industrial Average slipping 0.1% to 44,837.56.

Via Benzinga

Topics Stocks

Why Sarepta Therapeutics Stock Surged Nearly 48% In After-Hours Trading Today ↗

July 28, 2025

The FDA concluded that a recent patient death in Brazil was unrelated to Sarepta’s Elevidys treatment, allowing the company to resume U.S. shipments for boys who can still walk.

Via Stocktwits

HIMS and SRPT ALERTS: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm

July 28, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Sarepta Therapeutics Stock Soars After FDA Removes Hold On Elevidys For Some Patients ↗

July 28, 2025

Sarepta Therapeutics shares are halted in extended trading Monday after the U.S. Food and Drug Administration (FDA) recommended the removal of a voluntary hold for Elevidys.

Via Benzinga

FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy

July 28, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT

July 28, 2025

From Pomerantz LLP

Via GlobeNewswire

Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT

July 28, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT

July 28, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys ↗

July 28, 2025

FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment.

Via Benzinga

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)

July 28, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

Retail Bulls Stick With Sarepta After 8-Year-Old Patient’s Death Deemed Unrelated To DMD Gene Therapy ↗

July 28, 2025

The update comes as Sarepta faces mounting regulatory scrutiny, including an ongoing FDA investigation and a recommendation from European regulators to reject approval of Elevidys.

Via Stocktwits

Topics Death

Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS

July 25, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

July 25, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy ↗

July 25, 2025

Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.

Via Benzinga

Sarepta Stock Slumps After EU Regulator Recommends Refusing Approval To Its Contentious Gene Therapy: Retail Expects Stock Bounceback ↗

July 25, 2025

Roche announced on Friday that it plans to continue working with the EMA to explore a potential path forward.

Via Stocktwits

Topics Death

Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe ↗

July 25, 2025

Shares are down another double-digit percentage after bad news continued piling on for gene therapy Elevidys.

Via Investor's Business Daily

Topics Death

Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT

July 25, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT

July 25, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Intel, Absci, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

July 25, 2025

Via Benzinga

Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union

July 25, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Friday's pre-market session: top gainers and losers ↗

July 25, 2025

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 25, 2025

Via Benzinga

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm

July 24, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent' For Gene Therapies. ↗

July 24, 2025

Sarepta stock is now trading at a nine-year low as the debacle with its gene therapy, Elevidys, continues.

Via Investor's Business Daily

Topics Death Workforce

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 24, 2025

Via Benzinga

Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT

July 24, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT

July 24, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗

July 24, 2025

Via Benzinga

Is This Stock a Buy After Soaring by 20% in 1 Day? ↗

July 24, 2025

Via The Motley Fool

Topics Death

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.